Breaking News

Therapure, DVC Awarded DoD Contract

To manufacture materials for anti-nerve gas agent

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Therapure Biopharma has been selected as a subcontractor for DynPort Vaccine Co. LLC (DVC), which was awarded a contract with a maximum value of $157.3 million by the U.S. Department of Defense to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.   Therapure’s subcontract includes process optimization as well as manufacture of all clinical and nonclinical materials to support DVC’s contract to develop, test and obtain FDA ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters